Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Anti-IL-6-therapie bij refractaire gewrichts- en huidbetrokkenheid SSc
jan 2022 | Sclerodermie